Source: Korea Biomedical Review

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

Co-Founder & CEO

David Simpson

CEO Approval Rating

90/100

Iksuda is an England-based biotechnology company that develops and commercializes antibody therapies for the treatment of cancer.

Iksuda received $25M in Corporate Round Funding